

Minutes of the **Somerset Prescribing Forum** held in **Meeting Room 1, Wynford House, Lufton Way, Yeovil, Somerset** on **Wednesday 15th November 2017**

Present:	Dr Geoff Sharp (GS)	GP Delegate (Central Mendip Commissioning Locality), Chair
	Dr Clare Barlow (CB)	Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS FT
	Shaun Green (SG)	Associate Director, Head of Medicines Management, NHS Somerset CCG
	Catherine Henley (CH)	Medicines Manager, NHS Somerset CCG
	Sam Morris SJM	Medicines Manager, NHS Somerset CCG
	Liz Harewood (LH)	Somerset Partnership Representative
Apologies:	Jon Beard (JB)	Chief Pharmacist, Taunton & Somerset NHS FT
	Steve Du Bois (SDB)	Chief Pharmacist- Head of Medicines Management, Somerset Partnership NHS Foundation Trust
	Dr Orla Dunn (OD)	Consultant in Public Health, Somerset County Council
	Kate Jones (KJ)	Symphony lead pharmacist
	Ann Lee (AL)	Clinical Director, St Margaret's Hospice
	Andrew Prowse (JS)	Chief Pharmacist, Yeovil District Hospital
	Michael Lennox (ML)	Chief Officer, Somerset LPC
	Dr Robert Munro (RM)	GP, Somerset Local Medical Committee representative
	Jean Perry (JP)	Commissioning Manager, NHS Somerset CCG
	Zoe Talbot-White (ZT)	Prescribing Support Technician, NHS Somerset CCG

1	INTRODUCTIONS
	Geoff welcomed members to the meeting.
2	APOLOGIES
	Apologies were given, as detailed above.
3	DECLARATIONS of INTEREST
	No New Declarations.
4	MINUTES OF THE MEETING HELD ON 20th September 2017
	Review of action points:
	<p>Agreed as an accurate record, subject to the following changes: Point 7.3 to add:</p> <ul style="list-style-type: none"> • Neurology specialists, <u>care of the elderly and those with an interest in Parkinson's</u> only could begin trialling opicapone in a small cohort of patients over a period of a few months. <p style="text-align: right;">Action: SJM</p> <p>Most items were either complete or on the agenda. However, the following points were specifically noted:</p> <p>16. Sodium oxybate and pitolisant for symptom control of narcolepsy with cataplexy. SG has asked the CCG to adopt the NHSE position, and commission these</p>

	medicines in adults. Otherwise, there will be no funding for children to continue on these medicines once they become adults,
5	MATTERS ARISING
5.1	Antipsychotics in learning difficulties- SomPar Data
	<ul style="list-style-type: none"> • SomPar audit data- LH reported that they now have the data but it is not very useful because the audit did not look at the appropriateness of initiation of an antipsychotic. SomPar are reviewing and will share further information by January. Action: LH • It was noted that this was discussed at the recent prescribing leads meeting where Dr Sunil Ram (Learning Disability Consultant) presented on this topic.
5.2	Sompar request for dual use of cholinesterase inhibitors and memantine
	It was agreed that a decision couldn't be made without a formal application from SomPar.
5.3	LMWH Bridging Guidance –YDH update
	Standing item, no feedback at this time.
5.4	Disease Modifying Anti-Rheumatic Drug DMARD Monitoring shared care guideline
	A single Shared care Guideline (SCG), to cover all commonly used DMARDs is being written. However, this work is on hold until the national consultation on revised guidance around shared care is complete. CH to finalise. Action CH
5.5	Amended DVT Treatment Pathway
	To be updated following comments at PAMM this morning, Action SG
5.6	Osteoporosis - Intervention Thresholds
	<ul style="list-style-type: none"> • A new NICE TAG for the for the use bisphosphonates in the treatment of osteoporosis has been published, which recommends that anyone estimated to have a 1% ten year risk of an osteoporotic fracture, using FRAX or QFRACTURE (without a t-score) should be considered for bone protection. • SG explained that this should involve a conversation between the patient and their GP around FRAX score, risks v benefits and patient preference. • The CCG cannot set a treatment threshold. Use NICE guidance using FRAX scores and make a decision with the patient. For noting. • A revised DEXA scan policy has been issued, in line with the new NICE osteoporosis guidelines. DEXA scans are not routinely commissioned except, in a number clearly defined cases. For example, where 10-year risk of an osteoporotic fracture calculated using FRAX (without a DEXA scan) or QFRACTURE is very close to the treatment threshold.
6	OTHER ISSUES
6.1	Draft Revised Shared Care Prescribing Guidance
	<ul style="list-style-type: none"> • The CCG will not be formally responding to this consultation. Trusts should respond via their networks. <p>It was highlighted that GPs giving consent to shared care is important, but requiring a formal response creates extra workload. Work on local SCGs is current paused until this guidance is finalised, so that it can be referenced.</p>

7	Formulary Applications
7.1	MIB110 FreeStyle Libre for glucose monitoring criteria letter and Regional Medicines Optimisation Committee (RMOC) position
	<ul style="list-style-type: none"> The RMOC has published a position statement recommending that Freestyle Libre should be made available to almost all, type one diabetics. However, there statutory requirement that CCGs adopt this guidance. Guidance noted. The CCG has adopted a position of restricted criteria for type one diabetics only. These criteria have been published to local specialists and GPs. <p>We need to audit our restricted criteria to review whether we are sticking to the criteria.</p>
7.2	NACYSYS® Acetylcysteine effervescent tabs- £5.50 for 30 tabs
	<ul style="list-style-type: none"> Licensed acetylcysteine product. Currently supplied as an unlicensed special by acute trusts, so not recommended. Currently mainly used in secondary care, with some use in primary care. <p>Add to formulary; Amber TLS status Action: Steve Moore</p>
7.3	Fobumix 160/4.5mcg Easyhaler
	<ul style="list-style-type: none"> Fobumix Easyhaler is indicated for use in adults aged 18 years and over. It is indicated for asthma and the management of chronic obstructive pulmonary disease (COPD). Additional strengths to match the Symbicort range will be launched later this year. Adopt other strengths when they become licenced. <p>Add to formulary; Green TLS status Action: Steve Moore</p>
7.4	Eydelto® - Dorzolamide preservative free drops (£12.09 for 1 month)
	<ul style="list-style-type: none"> Saving noted. Add to formulary; Green TLS status Action: Steve Moore
7.5	Eylamdo® - Dorzolamide and Timolol preservative free drops (£14.29 for 1 month)
	<ul style="list-style-type: none"> Saving noted. Discussed shelf life of eye drops in secondary care setting. MPH has already moved to 28 day use. Add to formulary; Green TLS status Action: Steve Moore
8	DTC decisions and other reports
8.1	Somerset Partnership Mental Health D&TC –Next meeting 05/12/17
8.2	YDH D&TC – Last meeting 4/10/17 minutes received
	Noted the review of melatonin prescribing by paediatricians.
8.3	T&ST D&TC – Last meeting 10/11/17- minutes not received
	Discussed lidocaine patches. MPH is trialling the use after rib fracture. It was agreed that it should be restricted for initiation by the pain team only and that they should only give the patient a restricted course to take home. This should not be continued in primary care. Article to be added to the newsletter article to make this clear. Action: Steve Moore
8.4	T&S Antimicrobial Prescribing Group – Last meeting 09/08/17 – Minutes received
8.5	RUH Bath D&TC – Last meetings 17/08/17– no new minutes received.

8.6	BNSSG D&TC — no new minutes received
8.7	BNSSG Joint Formulary Group – no new minutes received
8.8	LPC report
	Part 2 – Items for Information or Noting
9	NICE Guidance (see link for guidance by month)
	NICE Technology Appraisals
9.1	TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (update to commercial arrangements for noting)
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS Action: Steve Moore
9.2	TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (update to commercial arrangements for noting)
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS Action: Steve Moore
9.3	TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (update to commercial arrangements for noting)
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS Action: Steve Moore
9.4	TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (update to commercial arrangements for noting)
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS Action: Steve Moore
9.5	TA477 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (for noting)
	NICE have approved this but it is NHSE commissioned.
9.6	TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (for noting)
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS Action: Steve Moore
9.7	TA479 Reslizumab for treating severe eosinophilic asthma (for noting)
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS Action: Steve Moore
9.8	TA480 Tofacitinib for moderate to severe rheumatoid arthritis (for noting)
	Positive appraisal; CCG commissioned.

	<p>First line oral drug The RA pathway needs to be updated. CCG to commission this from day 90, not immediately. Red TLS - update TLS with commissioning date</p>	<p>Action: SG Action: SM</p>
9.9	TA481 Immunosuppressive therapy for kidney transplant in adults (for noting)	
	Noted; NHSE commissioned.	
9.10	TA482 Immunosuppressive therapy for kidney transplant in children and young people (for noting)	
	Noted; NHSE commissioned.	
9.11	TA483 Nivolumab for previously treated squamous non-small-cell lung cancer (for noting)	
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS	Action: Steve Moore
9.12	TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer (for noting)	
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS	Action: Steve Moore
9.13	TA485 Sarilumab for moderate to severe rheumatoid arthritis (for noting)	
	<p>Positive appraisal; An additional treatment for RA approved, as per NICE. RA pathway will need to be updated. There are 3 biosimilar's cheaper than this. An injectable "me too" drug. Because of the deficit the CCG will commission from day 90. Medical director and chief pharmacist to be informed. RA pathway to be updated Red TLS status- CCG commissioned. Update TLS-</p>	<p>Action: SG Action: SG Action: SM</p>
9.15	TA487 Venetoclax for treating chronic lymphocytic leukaemia (for noting)	
	Positive appraisal; add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS - update TLS	Action: Steve Moore
9.16	TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (update to commercial arrangements for noting)	
	Noted	
9.17	TA417 Nivolumab for previously treated advanced renal cell carcinoma (update to commercial arrangements for noting)	
	Noted	
10	NICE Clinical Guidance	
10.1	CG28 Depression in children and young people: identification and management- update	
	Update noted	
10.2	CG54 Urinary tract infection in under 16s: diagnosis and management- update	
	Update noted	

10.3	CG71 Familial hypercholesterolaemia: identification and management- update
	The evidence on case finding, diagnosis and statin monotherapy was reviewed. Some new recommendations were added and some recommendations were updated. Nicotinic acid has been removed from the recommendations. A new recommendation cross-referring to the technology appraisal guidance on alirocumab and evolocumab has been added to section 1.3.1 Action to review: One of the audits in the quality improvement scheme covers this, so need to check that the audit is still appropriate. Action SG
10.4	CG89 Child maltreatment: when to suspect maltreatment in under 18s- update
	Update noted
10.5	CG165 Hepatitis B (chronic): diagnosis and management-
	Update noted
10.6	NG51 Sepsis: recognition, diagnosis and early management- update
	Update noted
10.7	NG74 Intermediate care including reablement- NEW
	Noted
10.8	NG75 Faltering growth: recognition and management of faltering growth in children- NEW
	Noted
10.9	NG76 Child abuse and neglect- NEW
	Noted
10.10	NG77 Cataracts in adults: management- NEW
	Noted
10.11	NG78 Cystic fibrosis: diagnosis and management- NEW
	Noted
10.12	NG79 Sinusitis (acute): antimicrobial prescribing- NEW
	Noted
10.13	NG81 Glaucoma: diagnosis and management- NEW
	Noted
11	Specialist Commissioning
12	PBR excluded drug monitoring
12.1	T & S
	CB raised that Avastin is on the list. Should it be there? SG to raise with TST as normally paid for through the CDF Action: SG

12.2	Yeovil
	Predicted £48k over spend .
13	Horizon Scanning
13.1	NICE forward planner - for noting
	Both trusts to horizon scan for new medicines that may affect the CCG PbR excluded budget for 18/19. Action: JB and AP
14	Safety items, NPSA Alerts and Signals
14.1	MHRA Drug Safety Update October
	Noted.
14.2	NHS England Patient Safety Alert: Risk of severe harm and death from infusing total parenteral nutrition too rapidly in babies
	Send reminder to CB Action: CH
15	BNF Changes
	BNF Update October
16	Any other business
16.1	A consultation has started to make gabapentin and pregabalin scheduled CDs
	Date of Next Meetings:
	Wednesday 17 th January 2018
	Wednesday 14 th March 2018
	Wednesday 23 rd May 2018
	Wednesday 18 th July 2018

SOMERSET PRESCRIBING FORUM

SCHEDULE OF ACTIONS ARISING FROM THE MEETING HELD ON 15th November 2017

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
1	Declarations of interest (1)	Members were asked to notify the Prescribing Forum secretary of any standing declarations of interest, which should be held on record.	All (on going)	Ongoing
2	Amend September Minutes	Amend as detailed above under point 4.	SJM 18 th January 2018	Complete
3	Antipsychotics in learning difficulties – SomPar data	Sompar to share further information on the LD audit before January.	SDB/ LH 18 th January 2018	Pending
4	DMARD Monitoring	A single SCG for all DMARDs incorporating the BSR Guidance has been worked on, but on hold for further feedback. CH to finalise.	CH 18 th January 2018	In progress
5	Amended DVT Treatment Pathway	To be updated following PAMM this morning.	SG 18 th January 2018	In progress
6	CG71 Familial hypercholesterolaemia: identification and management- update	One of the audits in the quality improvement scheme covers this, so need to check that the audit is still appropriate.	SG 18th January 2018	In progress
7	T & S	CB raised that Avastin is on the list. Should it be there? SG to raise with TST as normally paid for through the CDF	SG 18th January 2018	
8	NICE forward planner	Both trusts to horizon scan for new medicines that may affect the CCG PbR excluded budget for 18/19.	JB and AP 18th January 2018	
9	NHS England Patient Safety Alert	<u>Risk of severe harm and death from infusing total parenteral nutrition too rapidly in babies</u> Send reminder to CB	CH18th January 2018	
10	<u>TA480</u> Tofacitinib for moderate to severe rheumatoid arthritis <u>TA485</u> Sarilumab for moderate to severe rheumatoid arthritis	RA pathway needs to be updated Medical directors and Chief pharmacists to be informed about commissioning from day 90.	SG 18th January 2018	
11	Newsletter	Lidocaine patches- article to make agreement over secondary care prescribing to be made clear.	Steve Moore 17th January 18	

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
12	Formulary and Traffic Light System changes	<ul style="list-style-type: none"> • NACYSYS[®] Acetylcysteine effervescent tabs; Add to formulary; Amber TLS • Fobumix 160/4.5mcg Easyhaler • Adopt other strengths when they become licenced. Add to formulary; Green TLS • Eydelto[®]- Dorzolamide preservative free eye drops . Add to formulary; Green TLS • Eylamdo[®]- Dorzolamide and Timolol preservative free eye drops . Add to formulary; Green TLS • TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab- TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS • TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS • TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS • TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer. A add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS. • TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS. • TA479 Reslizumab for treating severe eosinophilic asthma. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS • TA480 Tofacitinib for moderate 	Steve Moore 17 th January 18	

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
		<p>to severe rheumatoid arthritis. The RA pathway needs to be updated. CCG to commission this from day 90. Red TLS - with commissioning date</p> <ul style="list-style-type: none"> • TA483 Nivolumab for previously treated squamous non-small-cell lung cancer. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS • TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS • TA485 Sarilumab for moderate to severe rheumatoid arthritis. An additional treatment for RA approved, as per NICE. CCG will commission from day 90. Red TLS status- update TLS with commissioning date. • TA487 Venetoclax for treating chronic lymphocytic leukaemia. Add to TLS as per NICE Guidance with note that this is NHSE commissioned. Red TLS 	<p>Steve Moore 17th January 18</p>	